In this article, Andrew Butcher writes about the importance of stakeholder engagement as effective but high-cost new therapies have potentially damaging financial implications for the healthcare systems expected to fund them. Regrettably, the pharmaceutical industry is often identified as the cause of the problems rather than the key players in solving them.
Evaluating Medicare Stars for cardiovascular disease patients
Considering that cardiovascular disease (CVD) remains the leading cause of death in the United States, particularly affecting the growing population of...